U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Showing 1 - 10 of 213 results

Status:
US Approved Rx (2019)
First approved in 2019

Class (Stereo):
CHEMICAL (EPIMERIC)



ODM-201 (also known as BAY-1841788) is a non-steroidal antiandrogen, specifically, a full and high-affinity antagonist of the androgen receptor (AR), that is under development by Orion and Bayer HealthCare for the treatment of advanced, castration-re...
Status:
US Approved Rx (2019)
First approved in 2019

Class (Stereo):
CHEMICAL (ABSOLUTE)



Allopregnanolone is a neurosteroid metabolite of progesterone. It is an allosteric modulator of inhibitory γ-aminobutyric acid (GABA-A) receptors on neural stem cells and other cell types in the brain. Allopregnanolone has effects similar to those of...
Status:
US Approved Rx (2017)
First approved in 2017

Class (Stereo):
CHEMICAL (ABSOLUTE)



Naldemedine (Symproic) is an opioid antagonist indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain. Naldemedine is an opioid antagonist with binding affinities for mu-, delta-, and kappa-opi...
Status:
US Approved Rx (2015)
First approved in 2015

Class (Stereo):
CHEMICAL (ABSOLUTE)



Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Swit...
Status:
US Approved Rx (2016)
First approved in 2014

Class (Stereo):
CHEMICAL (ABSOLUTE)


Conditions:

Dehydroepiandrosterone (INTRAROSA™, prasterone) is a major C19 steroid produced from cholesterol by the adrenal cortex. It is also produced in small quantities in the testis and the ovary. Dehydroepiandrosterone (INTRAROSA, prasterone) is structurall...
Status:
US Approved Rx (2012)
First approved in 2012

Class (Stereo):
CHEMICAL (ACHIRAL)



Axitinib (trade name Inlyta) is a small molecule tyrosine kinase inhibitor developed by Pfizer. It has been shown to significantly inhibit growth of breast cancer in animal (xenograft) models and has shown partial responses in clinical trials with re...
Status:
US Approved Rx (2020)
First approved in 2011

Class (Stereo):
CHEMICAL (ACHIRAL)

Targets:


Deferiprone (trade name Ferriprox) is an iron chelator indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate. Deferiprone is an orally bioavailable bidentate...
Status:
US Approved Rx (2020)
First approved in 2010

Class (Stereo):
CHEMICAL (ACHIRAL)



Dabigatran (Pradaxa, Prazaxa) is an anticoagulant medication that can be taken by mouth. FDA approved on October 19, 2010. Dabigatran directly inhibits thrombin in a concentration-dependent, reversible, specific, and competitive manner which results ...
Status:
US Approved Rx (2018)
First approved in 2008

Class (Stereo):
CHEMICAL (RACEMIC)



Desvenlafaxine is a dual serotonin and norepinephrine reuptake inhibitor in vitro and in vivo that demonstrates good brain-to-plasma ratios. Desvenlafaxine has demonstrated antidepressant effects in preclinical studies. Pfizer is developing an oral, ...
Status:
US Approved Rx (2007)
First approved in 2007

Class (Stereo):
CHEMICAL (ABSOLUTE)



Rotigotine is an agonist at all 5 dopamine receptor subtypes (D1-D5) but binds to the D3 receptor with the highest affinity. It is also an antagonist at α-2-adrenergic receptors and an agonist at the 5HT1A receptors. Rotigotine also inhibits dopamine...